JP2020500852A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500852A5 JP2020500852A5 JP2019526287A JP2019526287A JP2020500852A5 JP 2020500852 A5 JP2020500852 A5 JP 2020500852A5 JP 2019526287 A JP2019526287 A JP 2019526287A JP 2019526287 A JP2019526287 A JP 2019526287A JP 2020500852 A5 JP2020500852 A5 JP 2020500852A5
- Authority
- JP
- Japan
- Prior art keywords
- angptl8
- pharmaceutical composition
- inhibitor
- reduced
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423639P | 2016-11-17 | 2016-11-17 | |
| US62/423,639 | 2016-11-17 | ||
| PCT/US2017/062103 WO2018094112A1 (en) | 2016-11-17 | 2017-11-16 | Methods of treating obesity with anti-angptl8 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500852A JP2020500852A (ja) | 2020-01-16 |
| JP2020500852A5 true JP2020500852A5 (https=) | 2020-12-17 |
| JP7133551B2 JP7133551B2 (ja) | 2022-09-08 |
Family
ID=60655071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019526287A Active JP7133551B2 (ja) | 2016-11-17 | 2017-11-16 | 抗ａｎｇｐｔｌ８抗体を用いて肥満を処置する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10442856B2 (https=) |
| EP (1) | EP3541839A1 (https=) |
| JP (1) | JP7133551B2 (https=) |
| KR (1) | KR20190078650A (https=) |
| CN (1) | CN110036029A (https=) |
| AU (1) | AU2017363143B2 (https=) |
| CA (1) | CA3044249A1 (https=) |
| EA (1) | EA201991203A1 (https=) |
| IL (1) | IL266564A (https=) |
| MA (1) | MA46842A (https=) |
| MX (1) | MX382035B (https=) |
| WO (1) | WO2018094112A1 (https=) |
| ZA (1) | ZA201902608B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3201225B1 (en) | 2014-10-03 | 2020-08-19 | NGM Biopharmaceuticals, Inc. | Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| AU2018366122A1 (en) | 2017-11-10 | 2020-04-23 | Ngm Biopharmaceuticals, Inc. | ANGPTL8-binding agents and methods of use thereof |
| WO2019126194A1 (en) | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Angptl8 assay and uses thereof |
| TWI747098B (zh) | 2018-12-21 | 2021-11-21 | 美商美國禮來大藥廠 | 抗angptl3/8複合物抗體及其使用方法 |
| CN114423787B (zh) | 2019-07-19 | 2025-01-24 | 昂科里斯庞斯公司 | 免疫调节性抗体及其使用方法 |
| CN110694067A (zh) * | 2019-11-06 | 2020-01-17 | 首都医科大学附属北京安贞医院 | 一种抑制血管生成素样蛋白8的物质的应用 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| CN111690058B (zh) * | 2020-03-30 | 2021-02-05 | 三优生物医药(上海)有限公司 | 针对冠状病毒的具有中和活性的抗体及其用途 |
| CN119367545B (zh) * | 2025-01-02 | 2025-04-08 | 山东第一医科大学(山东省医学科学院) | 靶向干预ANGPTL8 mRNA在制备治疗高同型半胱氨酸血症药物中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
| US20030068623A1 (en) | 1997-06-16 | 2003-04-10 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7393663B2 (en) | 1997-08-01 | 2008-07-01 | Serono Genetics Institute S.A. | Expressed sequence tags and encoded human proteins |
| AU2577799A (en) | 1998-02-09 | 1999-08-23 | Human Genome Sciences, Inc. | 45 human secreted proteins |
| KR100510795B1 (en) | 1999-08-31 | 2005-08-30 | Compositions and Methods for the Treatment of Tumor | |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| US7537903B2 (en) | 2007-04-23 | 2009-05-26 | Board Of Regents, The University Of Texas System | FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner |
| BRPI0812384A2 (pt) | 2007-05-22 | 2014-12-02 | Novartis Ag | Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21 |
| EP2679234A3 (en) | 2009-12-02 | 2014-04-23 | Amgen Inc. | Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho |
| JO3274B1 (ar) | 2009-12-24 | 2018-09-16 | Regeneron Pharma | أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| EP3201225B1 (en) | 2014-10-03 | 2020-08-19 | NGM Biopharmaceuticals, Inc. | Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides |
| TW201713690A (zh) * | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| RS62769B1 (sr) * | 2016-04-08 | 2022-01-31 | Regeneron Pharma | Postupci za lečenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3 |
-
2017
- 2017-11-16 EA EA201991203A patent/EA201991203A1/ru unknown
- 2017-11-16 CN CN201780070860.4A patent/CN110036029A/zh active Pending
- 2017-11-16 EP EP17812128.1A patent/EP3541839A1/en active Pending
- 2017-11-16 CA CA3044249A patent/CA3044249A1/en not_active Abandoned
- 2017-11-16 JP JP2019526287A patent/JP7133551B2/ja active Active
- 2017-11-16 WO PCT/US2017/062103 patent/WO2018094112A1/en not_active Ceased
- 2017-11-16 AU AU2017363143A patent/AU2017363143B2/en not_active Expired - Fee Related
- 2017-11-16 KR KR1020197017245A patent/KR20190078650A/ko not_active Ceased
- 2017-11-16 MX MX2019005651A patent/MX382035B/es unknown
- 2017-11-16 MA MA046842A patent/MA46842A/fr unknown
- 2017-11-17 US US15/815,881 patent/US10442856B2/en active Active
-
2019
- 2019-04-24 ZA ZA2019/02608A patent/ZA201902608B/en unknown
- 2019-05-12 IL IL266564A patent/IL266564A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500852A5 (https=) | ||
| US20240209102A1 (en) | Methods of treating inflammatory conditions | |
| JP7559112B2 (ja) | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 | |
| TW202323296A (zh) | 組合療法 | |
| JP7420730B2 (ja) | 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体 | |
| US20200339697A1 (en) | Methods For Treating Obesity And Nonalcoholic Fatty Liver Disease Or Nonalcoholic Steatohepatitis Using Glucagon Receptor Antagonistic Antibodies | |
| AU2015273199B2 (en) | Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies | |
| JP2021193121A (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| JP2022126791A (ja) | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 | |
| JP2023515771A (ja) | 強皮症および関連する疾病の処置のための方法 | |
| JP2019528306A (ja) | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 | |
| US20260070996A1 (en) | Formulations for anti-insulin receptor antibody and uses thereof | |
| WO2017076804A1 (en) | Treatment paradigm | |
| WO2017062693A1 (en) | Methods for treating rare genetic disorders using glucagon receptor antagonistic antibodies | |
| EP3756679A1 (en) | Compositions for use in the treatment of insulin deficiency conditions | |
| CA3185718A1 (en) | Treatment of food allergy using anti-ige antibodies | |
| WO2025171378A1 (en) | Insulin receptor modulation for tumor associated hyperinsulinism | |
| WO2023227952A1 (en) | Methods and compositions for treatment of thyroid eye disease | |
| WO2021207667A1 (en) | Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards) | |
| EA045412B1 (ru) | Агонисты рецептора глюкагоноподобного пептида 1 и их применения | |
| WO2017064564A2 (en) | Therapeutic regimens for treating psoriatic arthritis with an anti-ccl20 antibody |